Cargando…

Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice

The nuclear receptor FXR acts as an intracellular bile salt sensor that regulates synthesis and transport of bile salts within their enterohepatic circulation. In addition, FXR is involved in control of a variety of crucial metabolic pathways. Four FXR splice variants are known, i.e. FXRα1-4. Althou...

Descripción completa

Detalles Bibliográficos
Autores principales: Boesjes, Marije, Bloks, Vincent W., Hageman, Jurre, Bos, Trijnie, van Dijk, Theo H., Havinga, Rick, Wolters, Henk, Jonker, Johan W., Kuipers, Folkert, Groen, Albert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266635/
https://www.ncbi.nlm.nih.gov/pubmed/25506828
http://dx.doi.org/10.1371/journal.pone.0115028
_version_ 1782349037066780672
author Boesjes, Marije
Bloks, Vincent W.
Hageman, Jurre
Bos, Trijnie
van Dijk, Theo H.
Havinga, Rick
Wolters, Henk
Jonker, Johan W.
Kuipers, Folkert
Groen, Albert K.
author_facet Boesjes, Marije
Bloks, Vincent W.
Hageman, Jurre
Bos, Trijnie
van Dijk, Theo H.
Havinga, Rick
Wolters, Henk
Jonker, Johan W.
Kuipers, Folkert
Groen, Albert K.
author_sort Boesjes, Marije
collection PubMed
description The nuclear receptor FXR acts as an intracellular bile salt sensor that regulates synthesis and transport of bile salts within their enterohepatic circulation. In addition, FXR is involved in control of a variety of crucial metabolic pathways. Four FXR splice variants are known, i.e. FXRα1-4. Although these isoforms show differences in spatial and temporal expression patterns as well as in transcriptional activity, the physiological relevance hereof has remained elusive. We have evaluated specific roles of hepatic FXRα2 and FXRα4 by stably expressing these isoforms using liver-specific self-complementary adeno-associated viral vectors in total body FXR knock-out mice. The hepatic gene expression profile of the FXR knock-out mice was largely normalized by both isoforms. Yet, differential effects were also apparent; FXRα2 was more effective in reducing elevated HDL levels and transrepressed hepatic expression of Cyp8b1, the regulator of cholate synthesis. The latter coincided with a switch in hydrophobicity of the bile salt pool. Furthermore, FXRα2-transduction caused an increased neutral sterol excretion compared to FXRα4 without affecting intestinal cholesterol absorption. Our data show, for the first time, that hepatic FXRα2 and FXRα4 differentially modulate bile salt and lipoprotein metabolism in mice.
format Online
Article
Text
id pubmed-4266635
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42666352014-12-26 Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice Boesjes, Marije Bloks, Vincent W. Hageman, Jurre Bos, Trijnie van Dijk, Theo H. Havinga, Rick Wolters, Henk Jonker, Johan W. Kuipers, Folkert Groen, Albert K. PLoS One Research Article The nuclear receptor FXR acts as an intracellular bile salt sensor that regulates synthesis and transport of bile salts within their enterohepatic circulation. In addition, FXR is involved in control of a variety of crucial metabolic pathways. Four FXR splice variants are known, i.e. FXRα1-4. Although these isoforms show differences in spatial and temporal expression patterns as well as in transcriptional activity, the physiological relevance hereof has remained elusive. We have evaluated specific roles of hepatic FXRα2 and FXRα4 by stably expressing these isoforms using liver-specific self-complementary adeno-associated viral vectors in total body FXR knock-out mice. The hepatic gene expression profile of the FXR knock-out mice was largely normalized by both isoforms. Yet, differential effects were also apparent; FXRα2 was more effective in reducing elevated HDL levels and transrepressed hepatic expression of Cyp8b1, the regulator of cholate synthesis. The latter coincided with a switch in hydrophobicity of the bile salt pool. Furthermore, FXRα2-transduction caused an increased neutral sterol excretion compared to FXRα4 without affecting intestinal cholesterol absorption. Our data show, for the first time, that hepatic FXRα2 and FXRα4 differentially modulate bile salt and lipoprotein metabolism in mice. Public Library of Science 2014-12-15 /pmc/articles/PMC4266635/ /pubmed/25506828 http://dx.doi.org/10.1371/journal.pone.0115028 Text en © 2014 Boesjes et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Boesjes, Marije
Bloks, Vincent W.
Hageman, Jurre
Bos, Trijnie
van Dijk, Theo H.
Havinga, Rick
Wolters, Henk
Jonker, Johan W.
Kuipers, Folkert
Groen, Albert K.
Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
title Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
title_full Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
title_fullStr Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
title_full_unstemmed Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
title_short Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
title_sort hepatic farnesoid x-receptor isoforms α2 and α4 differentially modulate bile salt and lipoprotein metabolism in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266635/
https://www.ncbi.nlm.nih.gov/pubmed/25506828
http://dx.doi.org/10.1371/journal.pone.0115028
work_keys_str_mv AT boesjesmarije hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT bloksvincentw hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT hagemanjurre hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT bostrijnie hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT vandijktheoh hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT havingarick hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT woltershenk hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT jonkerjohanw hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT kuipersfolkert hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice
AT groenalbertk hepaticfarnesoidxreceptorisoformsa2anda4differentiallymodulatebilesaltandlipoproteinmetabolisminmice